Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma
Shots:
- The PRIME designation is based on two Phase I/II studies in R/R cHL conducted at Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center
- The studies showed the complete disappearance of tumors in ~60% of patients at the highest dose level with no serious toxicities- associated with several other CAR-T therapies. The results were published in Clinical Oncology
- The company plans to commence a multi-center pivotal study in the US during 2021. Additionally- P-I clinical study for patients with r/r CD30 positive NHL is open for enrollment in the US
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com